Seaport Therapeutics has raised $225 million to advance a lead drug candidate for depression treatment, utilizing a platform technology called Glyph. The drug candidate, SPT-300, is a prodrug that converts into allopregnanolone to modulate the GABA-A receptor in the central nervous system. The new capital will help Seaport reach important clinical milestones. Additionally, other biotech companies such as Alpha-9 Oncology, AvenCell Therapeutics, and Tolerance Bio have secured significant funding for the development of various therapies. The trend reflects a growing interest in innovative healthcare solutions and the potential for new advancements in medicine.
Source link
Seaport Therapeutics Secures $225M for New Kind of Depression Drug
